Trial Profile
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Jan 2021 Status changed from active, no longer recruiting to completed.
- 27 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 30 Apr 2018 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019.